Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo
- PMID: 16224813
- DOI: 10.1002/eji.200535110
Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo
Abstract
Vitiligo is a skin disorder characterized by depigmented macules secondary to melanocyte loss. An unusual facet is its relation to melanoma: cytotoxic T lymphocytes directed to melanocyte antigens are found in both conditions and imply a breakdown of tolerance, yet the resulting immune reaction is the opposite. The mechanisms at the basis of these opposite effects are not known. Here, we performed a direct comparison of whole melanocyte-specific T cell populations in the two diseases. We demonstrate that neither precursor frequencies of Melan-A/MART-1-specific T lymphocytes nor their status of activation differ significantly. However, by using a tetramer-based T cell receptor down-regulation assay, we documented a higher affinity of vitiligo T cells. We calculated that the peptide concentration required for 50% of maximal receptor down-regulation differed by 6.5-fold between the two diseases. Moreover, only vitiligo T cells were capable of efficient receptor down-regulation and IFN-gamma production in response to HLA-matched melanoma cells, suggesting that this difference in receptor affinity is physiologically relevant. The differences in receptor affinity and tumor reactivity were confirmed by analyzing Melan-A/MART-1-specific clones established from the two diseases. Our results suggest that the quality, and not the quantity, of the melanocyte-specific cytotoxic responses differs between the two pathologies.
Similar articles
-
Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.J Invest Dermatol. 2001 Aug;117(2):326-32. doi: 10.1046/j.1523-1747.2001.01408.x. J Invest Dermatol. 2001. PMID: 11511311
-
Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.J Invest Dermatol. 2003 Aug;121(2):308-14. doi: 10.1046/j.1523-1747.2003.12368.x. J Invest Dermatol. 2003. PMID: 12880423
-
Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.J Invest Dermatol. 2003 Sep;121(3):550-6. doi: 10.1046/j.1523-1747.2003.12413.x. J Invest Dermatol. 2003. PMID: 12925214
-
Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?Pigment Cell Res. 2005 Aug;18(4):234-42. doi: 10.1111/j.1600-0749.2005.00244.x. Pigment Cell Res. 2005. PMID: 16029417 Review.
-
Identification of tumor-regression antigens in melanoma.Important Adv Oncol. 1996:3-21. Important Adv Oncol. 1996. PMID: 8791125 Review. No abstract available.
Cited by
-
Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure.Oncoimmunology. 2012 Mar 1;1(2):129-140. doi: 10.4161/onci.1.2.18216. Oncoimmunology. 2012. PMID: 22720234 Free PMC article.
-
Nonsegmental vitiligo and autoimmune mechanism.Dermatol Res Pract. 2011;2011:518090. doi: 10.1155/2011/518090. Epub 2011 Jul 26. Dermatol Res Pract. 2011. PMID: 21804820 Free PMC article.
-
Tumor rejection properties of gp100209-specific T cells correlate with T cell receptor binding affinity towards the wild type rather than anchor-modified antigen.Mol Immunol. 2021 Jul;135:365-372. doi: 10.1016/j.molimm.2021.05.001. Epub 2021 May 11. Mol Immunol. 2021. PMID: 33990005 Free PMC article.
-
T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity.Int Rev Immunol. 2006 May-Aug;25(3-4):235-58. doi: 10.1080/08830180600743081. Int Rev Immunol. 2006. PMID: 16818373 Free PMC article. Review.
-
A Comparative Analysis Dissecting the Immune Landscape of Vitiligo and Melanoma from a single-cell Perspective: Two Sides of the Same Coin?Inflammation. 2025 Jul 3. doi: 10.1007/s10753-025-02332-2. Online ahead of print. Inflammation. 2025. PMID: 40608219
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials